SCHEMBL21458331

SCHEMBL21458331

COC(=O)c1ccc(Br)c2cnn(Cc3ccc(-c4ccccc4)cc3)c12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
NPBWR1 P48145 1/20 0.42
PKM P14618 2/20 0.40
PKLR P30613 1/20 0.40
ADORA2A P29274 2/20 0.39
ADORA1 P30542 2/20 0.39
ERCC5 P28715 1/20 0.39
FEN1 P39748 1/20 0.39
EGLN1 Q9GZT9 1/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
NR4A2 P43354 1/20 0.39
CYP1A2 P05177 1/20 0.39
FAAH O00519 1/20 0.39
MGLL Q99685 1/20 0.39
MAPT P10636 2/20 0.39
NPC1 O15118 1/20 0.39
LMNA P02545 1/20 0.39
TP53 P04637 1/20 0.39
TSHR P16473 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26602905 0.88 MEN1 (0.43) MEN1KMT2ANPBWR1PKMPKLR
SCHEMBL21458330 0.87 ALDH1A1 (0.44) MEN1KMT2ANPBWR1PKMPKLR
SCHEMBL30843256 0.87 ALDH1A1 (0.44) MEN1KMT2ANPBWR1PKMPKLR
SCHEMBL24774583 0.83 MEN1 (0.40) MEN1KMT2ANPBWR1PKMPKLR
SCHEMBL30843261 0.83 MEN1 (0.39) MEN1KMT2ANPBWR1PKMPKLR
SCHEMBL21458324 0.83 MEN1 (0.39) MEN1KMT2ANPBWR1PKMPKLR
SCHEMBL24774860 0.82 MEN1 (0.39) MEN1KMT2ANPBWR1PKMPKLR
SCHEMBL21481753 0.81 UCHL1 (0.47) MEN1KMT2ANPBWR1PKMPKLR
SCHEMBL24774850 0.80 MEN1 (0.38) MEN1KMT2ANPBWR1PKMPKLR
SCHEMBL28450982 0.80 SMN1; SMN2 (0.44) MEN1KMT2ANPBWR1PKMADORA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250353829-A1 BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF TEMPEST THERAPEUTICS INC (US) 2025-11-20 US disclosed
US-12215093-B2 Bicyclic carboxamides and methods of use thereof TEMPEST THERAPEUTICS, INC. (US) 2025-02-04 US disclosed
EP-3781550-B1 BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF TEMPEST THERAPEUTICS INC (US) 2024-10-30 EP disclosed
US-20240150316-A1 BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF TEMPEST THERAPEUTICS, INC. 2024-05-09 US disclosed
CN-112313208-B Bicyclic carboxamides and methods of use thereof 泰普斯特医疗公司 2024-04-19 CN disclosed
US-11795156-B2 Bicyclic carboxamides and methods of use thereof TEMPEST THERAPEUTICS, INC. (US) 2023-10-24 US disclosed
US-11795156-B2 Bicyclic carboxamides and methods of use thereof TEMPEST THERAPEUTICS, INC. (US) 2023-10-24 US disclosed
US-11795156-B2 Bicyclic carboxamides and methods of use thereof TEMPEST THERAPEUTICS, INC. (US) 2023-10-24 US disclosed
US-20230045612-A1 BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF TEMPEST THERAPEUTICS, INC. 2023-02-09 US disclosed
WO-2022257961-A1 BENZOHETEROCYCLIC COMPOUND FOR TREATING EP2 AND EP4 RECEPTOR-MEDIATED DISEASES 武汉人福创新药物研发中心有限公司 2022-12-15 WO disclosed
CN-115448882-A Benzoheterocyclic compounds useful for the treatment of EP2, EP4 receptor mediated diseases 武汉人福创新药物研发中心有限公司 2022-12-09 CN disclosed
US-11472789-B2 Bicyclic carboxamides and methods of use thereof TEMPEST THERAPEUTICS, INC. (US) 2022-10-18 US disclosed
US-10968201-B2 Bicyclic carboxamides and methods of use thereof TEMPEST THERAPEUTICS, INC. (US) 2021-04-06 US disclosed
CN-112313208-A Bicyclic carboxamides and methods of use thereof 泰普斯特医疗公司 2021-02-02 CN disclosed
US-20210024491-A1 BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF TEMPEST THERAPEUTICS, INC. 2021-01-28 US disclosed
WO-2019204523-A1 BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF TEMPEST THERAPEUTICS, INC. (US) 2019-10-24 WO disclosed
US-20190315712-A1 BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF TEMPEST THERAPEUTICS, INC. 2019-10-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11795156-B2 Bicyclic carboxamides and methods of use thereof PTGER4, PTGER2, CNR2 MEN1 4314/4885KMT2A 829/4885NPBWR1 635/4885
US-10968201-B2 Bicyclic carboxamides and methods of use thereof PTGER4, PTGER2, CNR2 MEN1 4314/4885KMT2A 829/4885NPBWR1 635/4885
US-20240150316-A1 BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF PTGER4, PTGER2, CNR2 MEN1 4314/4885KMT2A 829/4885NPBWR1 635/4885
US-11472789-B2 Bicyclic carboxamides and methods of use thereof PTGER4, PTGER2, CNR2 MEN1 4314/4885KMT2A 829/4885NPBWR1 635/4885
US-20230045612-A1 BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF PTGER4, PTGER2, CNR2 MEN1 4314/4885KMT2A 829/4885NPBWR1 635/4885
US-20210024491-A1 BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF PTGER4, PTGER2, CNR2 MEN1 4314/4885KMT2A 829/4885NPBWR1 635/4885
US-20250353829-A1 BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF PTGER4, PTGER2, CNR2 MEN1 4314/4885KMT2A 829/4885NPBWR1 635/4885
US-12215093-B2 Bicyclic carboxamides and methods of use thereof PTGER4, PTGER2, CNR2 MEN1 4314/4885KMT2A 829/4885NPBWR1 635/4885
US-20190315712-A1 BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF PTGER4, PTGER2, CNR2 MEN1 4314/4885KMT2A 829/4885NPBWR1 635/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.